Aravive (ARAV) Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARAV shares.
View ARAV analyst ratings or view top-rated stocks.

5 Wall Street research analysts have issued 12-month price targets for Aravive's stock. Their ARAV share price forecasts range from $2.00 to $12.00. On average, they expect the company's stock price to reach $9.20 in the next year. This suggests a possible upside of 464.4% from the stock's current price.
View analysts price targets for ARAV or view top-rated stocks among Wall Street analysts.

Aravive's stock was trading at $1.32 at the beginning of the year. Since then, ARAV stock has increased by 23.5% and is now trading at $1.63.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ARAV earnings forecast.

Aravive, Inc. (NASDAQ:ARAV) announced its quarterly earnings results on Wednesday, March, 15th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.13. The firm had revenue of $1.47 million for the quarter, compared to analyst estimates of $0.37 million. Aravive had a negative net margin of 1,187.30% and a negative trailing twelve-month return on equity of 1,865.78%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aravive investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Applied Genetic Technologies (AGTC), Flexion Therapeutics (FLXN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Arbutus Biopharma (ABUS) and BioCryst Pharmaceuticals (BCRX).

Aravive trades on the NASDAQ under the ticker symbol "ARAV."

Aravive's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.36%), BlackRock Inc. (0.35%), Assenagon Asset Management S.A. (0.33%), Two Sigma Advisers LP (0.27%), Renaissance Technologies LLC (0.26%) and Jane Street Group LLC (0.11%). Insiders that own company stock include Amato Giaccia, Gail Frances Mcintyre and Vinay Shah.
View institutional ownership trends.

Shares of ARAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARAV stock can currently be purchased for approximately $1.63.

Aravive (NASDAQ:ARAV) has a market capitalization of $97.56 million and generates $9.14 million in revenue each year. The company earns $-76,320,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis.

Aravive's mailing address is River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098. The official website for the company is www.aravive.com. The company can be reached via phone at (936) 355-1910 or via email at christina@sternir.com.